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Abstract
Background: Ewing Sarcoma (EWS) is a mesenchymal-derived tumor that generally arises in bone and soft tissue. Intensive
research regarding the pathogenesis of EWS has been insufficient to pinpoint the early events of Ewing sarcomagenesis.
However, the Mesenchymal Stem Cell (MSC) is currently accepted as the most probable cell of origin.
Materials and Methods: In an initial study regarding a deep characterization of MSC obtained specifically from EWS patients
(MSC-P), we compared them with MSC derived from healthy donors (MSC-HD) and EWS cell lines. We evaluated the
presence of the EWS-FLI1 gene fusion and EWSR1 gene rearrangements in MSC-P. The presence of the EWS transcript was
confirmed by q-RT-PCR. In order to determine early events possibly involved in malignant transformation, we used a
multiparameter quantitative strategy that included both MSC immunophenotypic negative/positive markers, and EWS
intrinsic phenotypical features. Markers CD105, CD90, CD34 and CD45 were confirmed in EWS samples.
Results: We determined that MSC-P lack the most prevalent gene fusion, EWSR1-FLI1 as well as EWSR1 gene
rearrangements. Our study also revealed that MSC-P are more alike to MSC-HD than to EWS cells. Nonetheless, we also
observed that EWS cells had a few overlapping features with MSC. As a relevant example, also MSC showed CD99
expression, hallmark of EWS diagnosis. However, we observed that, in contrast to EWS cells, MSC were not sensitive to the
inhibition of CD99.
Conclusions: In conclusion, our results suggest that MSC from EWS patients behave like MSC-HD and are phenotypically
different from EWS cells, thus raising important questions regarding MSC role in sarcomagenesis.
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Introduction
EWS is a malignant mesenchymal-derived tumor that mainly
affects children and young adults. EWS usually arises in bone and
soft tissue and is characterized by the presence of a chromosomal
translocation between the EWSR1 gene, in the vast majority of
cases, and a member of the ETS family of genes, typically FLI1
[1]. This gene fusion encodes a chimerical protein responsible for
the transcriptional deregulation of target genes such as the
membrane receptor CD99 [1–3]. Currently, consensus about the
cell of origin of EWS is lacking. This has long been the focus of
intensive research and despite recent studies on Neural Crest Stem
Cells (NCSC) also suggesting that NCSC can be permissive to
EWS fusion, the Mesenchymal Stem Cell (MSC) compartment has
been proposed as the most acceptable possibility [1,4–9]. Together
with the usual primary location of EWS in mesoderm-derived
tissue, in vitro and in vivo evidence, suggests that MSC may be able
to transform into sarcoma-like-cells [10–15]. Moreover, EWSR1-
FLI1 knockdown shifts gene expression profile from EWS towards
an MSC-like signature [16]. Furthermore, the ectopic expression
of the EWSR1 fusion in mouse MSC led to tumor development
with overlapping features with EWS, namely CD99 overexpres-
sion [4]. However these studies were performed in MSC-HD or
mouse MSC, while to date MSC-P have never been studied
[4,10,11,17]. This fact limits our current knowledge regarding
their specific role in sarcomagenesis. More importantly, previous
studies performed in MSC derived from cancer patients other than
sarcomas, namely multiple myeloma or myelodysplastic syndrome,
have shown that in comparison with MSC-HD, MSC from
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patients exhibit a different genomic or transcriptomic profile
[18,19]. Herein, we characterized MSC-P according to their
phenotypical profile and presence of the EWS gene fusion. Our
results revealed that MSC-P behave as MSC-HD thus raising
important questions regarding their role in EWS sarcomagenesis.
Materials and Methods
MSC isolation, expansion and long-term culture
Bone Marrow (BM) samples were harvested by aspiration from
the iliac crest from molecularly-confirmed EWS patients under
general anesthesia. If the primary tumor was located in the iliac
bone, the contra-lateral site was used for BM harvesting (Table 1).
The ethical committee of the Rizzoli Institute, LUMC and
HUSAL approved the studies, and written informed consent was
obtained from all subjects involved. BM mononuclear cells were
isolated by Ficoll density gradient separation. Washed cells were
resuspended in Dulbecco’s modified Eagle’s-low glucose medium
(Gibco, Life Technologies) supplemented with 10% Fetal Bovine
Serum (FBS) and Penicillin/Streptomycin (P/S). Cultures were
maintained at 37uC in 75 cm2 flasks. When cultures reached
approximately 70% confluence, cells were detached by treatment
with trypsin/EDTA and replated, non-adherent cells were
discarded. Cells were stained with trypan blue (Sigma) and
counted in a Neubauer chamber. Cells were divided up to a
maximum of 6 times. A similar approach was used regarding
MSC-HD and MSC from healthy tissues. For full description refer
to supplemental data.
EWS tumor samples
Frozen tissue from EWS samples, (n = 9) were used to assess the
expression of CD90, CD105, CD34 and CD45. All H&E and
CD99 stained sections were carefully examined by experienced
pathologists, confirming the diagnosis.
EWS cell lines culture
EWS cell lines TC71; RM82; RD-ES; STAET1 and A4573
were cultured in RPMI medium (Gibco) with 10% FBS (Gibco).
A673 cell line was cultured in DMEM medium supplemented with
10%FBS. STAET 10, CADO-ES and STAET2.1 were cultured
in RPMI medium supplemented with 20%FBS. All media were
supplemented with 1% Glutamine (Gibco) and 1% P/S (Gibco).
Cell lines have been previously characterized within the
EUROBONET consortium [20].
Multiparameter Flow Cytometry
Cells were collected as described earlier and 26105 cells were
used for each tube.Multiparameter flow cytometry (MFC)
immunophenotypic studies were performed with the following
monoclonal antibody (MAb) combinations: AF700/AmCyan//
PerCPCy5.5/PacificBlue/PE/FITC/APC/PerCPCy7):CD90/CD
45/CD34/CD105/CD99, CD166, CD271/CD54, CD106,CD
19/CD117,CD73,HLA-DR/CD14, CD13 and CD10 (Table S1
in File S1). Cells were stained with the appropriate conjugation of
MAb and incubated out of light for 15 minutes. (Table S2 in File
S1) For CD99 staining, functional studies were performed by
indirect immunofluorescence using cloneO13 (Signet, Dedham,
MA), as primary antibody diluted 1:80 and goat anti-mouse FITC
(Pierce Biotechnology, Rockford, IL), diluted 1:100, as secondary
antibody.
Fluorescence in situ hybridization (FISH)
We used a commercial EWSR1 break-apart FISH probe
(Abbott-Vysis) for the detection of ES fusion transcripts. Further-
more, an additional, home-made dual-colour FISH probe for the
detection of EWSR1-FLI1 rearrangements was developed as
follows: three BAC clones (CTD-2307I11, RP11-53D4, CTD-
2126E12) spanning the chromosomal region (chr11q24.3) and two
BAC clones (RP11-367E7, RP11-480L23) spanning a region on
chromosome (chr22q12.1-12.2) were labeled with spectrum green-
dUTP (green signal) (Vysis Downers Grove, IL) and spectrum red-
Table 1. CD99 intensity levels on MSC-P as assessed by Multiparameter Flow Cytometry.
Sample CD99 MFI1 PN 2 Age Fusion type Primary tumor Remarks
MSC-P-01 + P1 12 EWSR1-FLI1 Humerus -
MSC-P-02 + P2 15 EWSR1 BA3 positive Intramuscular -
MSC-P-03 + P3 18 EWSR1-FLI1 Humerus -
MSC-P-05 + P1 17 EWSR1-FLI1 Iliac crest -
MSC-P-07 + P2 20 EWSR1 BA3 positive Fibula -
MSC-P-08 +/2 P2 17 EWSR1 BA3 positive Fibula -
MSC-P-09 + P3 24 EWSR1 BA3 positive Rib -
MSC-P-10 + P2 21 EWSR1 BA3 positive Th7 -
MSC-P-11 +/2 P2 29 EWSR1-FLI1 Iliac crest MD4
MSC-P-12 +/2 P3 19 EWSR1 BA3 positive L1 vertebra MD4
MSC-P-13 + P2 31 EWSR1 BA3 positive Humerus -
All samples were positive for CD99 with low to moderate levels of intensity. Samples were analyzed at low passages (1–3). Primary tumors were located in distinct
locations and all presented EWSR1 gene rearrangements and EWS-FLI 1 fusion in some cases. This situation was analyzed with comparison to a control which is the
median of all tubes without antibody and intensity levels were calculated with ration between sample/control. (ratio,122; ratio around 12; ratio = 1, +/2, ratio.2 +,
ratio.10 ++, ratio.100 +++).
1MFI stands for Median Fluorescence Intensity,
2PN stands for Passage Number;
3BA stands for Break Apart;
4MD stands for Metastasis at diagnosis.
doi:10.1371/journal.pone.0085814.t001
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dUTP, respectively, by nick translation (Vysis) and purified after
adding 10 mg of COT-1 (Invitrogen, Carlsbad, CA). To check the
specificity of this probe, hybridizations were performed over
metaphases of peripheral blood cells from healthy donors. FISH
procedure was performed as previously described, on 2-mm-thick
sections [21]. A volume of 10 ml of the diluted probes was applied
to the slides. The slide was covered with a glass coverslip and
sealed with rubber cement. Using a Hybrite machine (Vysis),
denaturation was 75uC for 5 min and hybridization was at 37uC
for at least 16 h. After removing the coverslips posthybridization
washing was done at 46uC in 26SSC, 50%formamide for 5 min
and stained with DAPI (6-diamidino-2-phenylindole) and mount-
ed with Vectashield H-1000 medium (Vector). Digital images were
obtained using a Zeiss Axioplan2 epifluorescence microscope (Carl
Zeiss Oberkochen, Germany) equipped with a digital camera
(ORCA-ER-1394, Hamamatsu Photonics KK, Hamamatsu,
Japan). In all cases, 100 nuclei were counted. TC71 cell line was
used as a positive control of EWSR1-FLI 1 rearrangement.
Differentiation Assays
A minimum of 56104 MSC were cultured on glass slides for two
days in cell culture medium. Afterwards, cells were cultured for 21
additional days in the appropriate differentiation medium, as
described elsewhere [18]. For full description refer to supplemental
data.
Immunohistochemistry
Immunohistochemistry (IHC) was carried out on sections of
frozen tissue using the Envision method (Dako, CA, USA) and
primary antibodies for CD105 and CD90; CD45; CD34 and
CD99 (abcam). IHC staining was evaluated by two pathologists
RNA extraction and qRT-PCR
RNA was extracted using Qiagen RNA mini Kit according to
manufacter’s instructions. 1 ug of RNA was used to produce
cDNA and q-RT-PCR was performed as previously described
[24]. The following primers were used for housekeeping gene
GAPDH: Forward: GCTCCTCCT GTTCGACAGTCA;Re-
Figure 1. Characterization of MSC. (A) In vitro differentiation potential of MSC. In vitro adipogenic differentiation. Representative images show
the light microscopic view of lipid drop accumulation after 3 weeks of culture in control medium and in differentiation induction medium. In vitro
chondrogenic potential of MSC. Representative images show the light microscopic view of alkaline phosphatase activity (detected by a blue-dark
staining) and mineralization after culture in control medium and in differentiation induction medium (detected by red staining). (B) Growth rate
evaluation in MSC-HD and MSC-P. Cells were counted with trypan blue at each passage. Trypan blue selectively colors dead cell in blue whereas live
cells are observed shinning since this marker is unable to enter the cytoplasm when the cell membrane in intact. Both sets of samples presented
similar growth rates and were in continuous growth during these experiments. (C) Immunophenotypic characterization of MSC: positive expression
of CD105, CD90, CD73 and CD106 and negative expression of hematopoietic markers CD34, CD45, CD19 and HLA-DR (light gray represents control
and darker gray represents sample with antibody).
doi:10.1371/journal.pone.0085814.g001
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verse: AATCCGTTGACTCCGACCTTC; and EWS transcripts:
i) EWS-FLI-1 type-1 Forward: ATCCTACAGCCAAGCTC-
CAAGTCA ;EWS-FLI1-type-1 Reverse: ATAA-
GAAGGGTTCTGCTGCCCGTAG; ii) EWS-FLI-1-type-2 For-
ward: GATCCTACAGCCAAGCTCCAAGTCA; EWS-FLI-1-
type-2 Reverse: GATTGGTGGTGTGGGAGGTTGTAT; iii)
EWS-FLI-1-type -3 Forward:GAGAGCGAGGTGGCTTCAAT;
EWS-FLI-1-type-3 Reverse: CCCAAGCTCCTCTTCTGACTG
and iv) EWS-ERG Forward: CCTACAGCCAAGCTC-
CAAGTC; EWS-ERG Reverse: GGAAGGAGATGGTTGAG-
CAG.
Treatments with anti-CD99 MAbs to evaluate apoptosis-
induction
The anti-CD99 0662 MAb was kindly provided by G. Bernard,
INSERM 343, Hospital de l’Archet, Nice, France [22]. Here,
26106 MSC suspended in 200 ml were incubated IMDM 10%FBS
with or w/o 10 mg/ml of 0662MAb. After the indicated time-
points, control and treated samples were washed and evaluated for
Annexin-V–Propidium Iodide evaluation accordingly to the
manufacture’s instructions (Mebcyto Kit, MBL).
Data analysis
Hierarchical clustering analysis performed with MFC data was
carried out using MSC-P (n = 11), MSC-HD (n = 6), MSC-
Adipose derived (n = 1), MSC-Placenta derived (n = 1) and EWS
cell lines (n = 9) in which all markers of the previous panel had
been tested. Clustering was run using standard correlation
coefficients, for the cluster method, a similarity metric and
average linkages were used. The Median Fluorescence Intensity
(MFI) value obtained for each tested marker was stored into a
database and a ratio between the MFI obtained for each marker
and the mean MFI value obtained for that marker in all samples
tested was then calculated. A table with the percentage of cells
analysed for each cell surface marker is shown in Table S2 in File
S1. Clustering was performed after median centering and
normalizing the fluorescence ratios. A logarithmic (base 2)
transformation was applied to the values of this ratio for individual
data sets. The resulting normalized log2 ratios were used for
further statistical analyses with the J-Express Pro V2.1 software
(MolMine AS, Bergen, Norway).
Statistics
Statistical analysis was performed with PAWS (SPSS Inc,
Chicago, IL). U-Mann Whitney test was used to look for
Figure 2. MSC-P lack the presence of the EWSR1-FLI1 chromosomal translocation. (A) Study of the chromosomal translocation between
genes EWSR1 and FLI1 using a EWSR1-FLI 1 homemade-fusion probe(1–3). MSC-P showed two normal copies of both EWSR1 and FLI1 (1 and 2)
whereas in the TC71 cell line we observed not only two normal copies but also one EWSR1-FLI1 fusion, marked by a white arrow (3) Rearrangements
of the EWSR1 gene were studied using a EWSR1 break-apart probe. (4–6) Representative images of MSC-P, EWS-P-01 and EWS-P-02, (4 and 5) failed to
present a break in the EWSR1 gene, whereas the positive control here represented by the TC71 cell line (6), showed a distinctive rearrangement of
this gene, marked by white arrows. (B) Results were validated by q-RT-PCR using EWS cell lines as a positive control. MSC-P, here represented by
Patients 1;2;3;5;6 and 7 as well a healthy donor display a clear negative expression of all the transcripts.
doi:10.1371/journal.pone.0085814.g002
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significant differences between groups (p values,0.05) and chi-




All samples were fully characterized according to the Interna-
tional Society for Cellular Therapy (ISCT) regarding i) differen-
tiation potential, ii) plastic adherence and iii) determination of
positive/negative surface antigens) [23]. After 21 days of treatment
with adipogenic differentiation medium, lipid droplets were
observed, confirming their potential to differentiate into adipo-
blasts (Figure 1A top panel). MSC were also able to differentiate
into osteoblasts which display alkaline phosphatase activity
together with calcium deposits (Figure 1A bottom panel). In
addition, MSC showed chondrogenic ability, as confirmed by
strong collagen type II positivity (Figure 1A upper-right
picture). All MSC presented plastic adherence. MSC-HD and
MSC-P had similar growth rate as observed in Figure 1B.
Moreover, the samples exhibited a positive expression for the
markers: CD105, CD90, CD73 as well as the adhesion molecule
CD166. Conversely, the hematopoietic lineage markers CD34,
CD45, CD19 and HLA-DR were not found (Figure 1C).
MSC derived from EWS Patients lack EWSR1 gene
rearrangements
We next explored the presence of the EWSR1-FLI1 gene fusion
in MSC-P in all cases. We observed that they lacked this chimeric
gene. (Figure 2A, pictures 1 and 2). Subsequently, we assessed
Figure 3. Immunophenotype of MSC-P versus EWS cells. (A) Comparative study between MSC-HD and MSC-P regarding EWS markers: CD271,
CD54 and CD117. The expression levels of the EWS markers CD271, CD54 and CD117 were evaluated by MFC and medium values of MFI are
represented by groups. (* represent p U-Mann Whitney,0,05 for MSC-P versus MSC-HD and ** p U-Mann Whitney,0,001 for MSC-P versus EWS cell
lines). All EWS cell lines present positive expression of CD271, when compared to the control. EWS cell lines show weak expression of CD54 when
compared to the control, with the exception of RDES and STAET1 cell lines with strong positive expression values. EWS cell lines present a
heterogeneous expression of CD117. (B) Table 1 represents CD99 expression in EWS cell lines. EWS cells presented a rather heterogeneous pattern;
nonetheless all cell lines studied here were positive for CD99 expression. Cell lines such as A673 and Cado-ES presented higher levels (score +++) of
CD99 expression, whereas RDES cell line presented the lowest levels (score +) of expression. This situation was analyzed with comparison to a control
which is the median of all tubes without antibody and intensity levels were calculated with ration between sample/control. (ratio,12 2; ration
around 1, 2 ; ratio = 1, +/2, ratio .2 +, ratio.10 ++, ratio.100 +++). (C) CD99 expression in MSC-P and EWS cell lines. CD99 expression is variable
within both groups and similar between the two groups of MSC samples, ranging from weak to moderate, and always lower that the EWS cell lines
tested here. (* p Mann-Whitney,0,05 EWS cell lines versus MSC and MSC-P versus EWS cell lines).
doi:10.1371/journal.pone.0085814.g003
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the presence of possible rearrangements of the EWSR1 gene. We
observed that MSC-P had no rearrangements of this gene
(Figure 2A, pictures 4 and 5). As expected, the EWS cell lines
showed a break on the EWSR1 gene and the fusion gene EWSR1-
FLI1 (Figure 2A, pictures 3 and 6, respectively), therefore
these were used as a control. In order to validate this result we also
performed qRT-PCR for the various EWS transcripts in BM-
hMSC samples. In Figure 2B, it may be observed that in
comparison to EWS cell lines bearing the different transcripts:
TC71 (EWS-FLI-1-type 1; Cado-ES (EWS-ERG); RDES (EWS-
FLI1-type 2) and A4573 (EWS-Fli-type 3), MSC-P did not show
these transcripts.
MSC derived from EWS Patients have a low expression of
EWS markers
The precise immunophenotypic profile of EWS cells has never
been fully established. Here, we analyzed the expression of
CD271, CD54 and CD117 in a panel of EWS cell lines
(Figure 3A).
CD271, the low affinity nerve growth factor receptor, displayed
a heterogeneous expression pattern among the different EWS cell
lines (Figure 3A). CD271 has also been reported to be expressed
in MSC. In this sense, here we observed a significantly higher
expression of CD271 in MSC-HD as compared to MSC-P
(p = 0.01) (Figure 3A). However, it is worth noting that both
MSC-HD and MSC-P presented significantly lower levels of this
marker than EWS cell lines (p,0.05) (Figure 3A).
CD54 (ICAM-1), an adhesion molecule involved in cell-matrix-
cell interactions, was found weakly expressed by all EWS cell lines,
with the exception of RDES and STAET 1 (Figure 3A).
Similarly, CD54 was weakly expressed in MSC, however it was
slightly more expressed in MSC-HD compared to MSC-P
(Figure 3A).
CD117 (C-KIT) has been extensively described as a tyrosine-
kinase receptor overexpressed in EWS cell lines and EWS tumor
samples [24,25,26]. Consistently, most of the EWS cell lines
studied here displayed high CD117 expression levels (Figure 3A).
C-KIT, showed a similar expression in MSC-HD and MSC-P, but
its expression was significantly lower than in the EWS cell lines
(p = 0.001) (Figure 3A).
The plasma membrane expression pattern of EWS cell
lines is globally different from that of MSC
After studying the presence of EWS markers in MSC, we
performed the opposite approach, in which we evaluated the
presence of an exhaustive panel of MSC markers in EWS cell lines
(n = 9). We performed a hierarchical unsupervised cluster analysis
to compare the expression of MSC-positive markers, MSC-
negative markers and EWS markers in all samples. We observed a
clear division into two clusters, one consisting of all the EWS cell
lines and another consisting of all MSC samples (n = 19), which
Figure 4. Comparative study between MSC, EWS cell lines and EWS samples. (A) Hierarchical unsupervised cluster analysis showed two
different clusters, one consisting of all EWS cell lines and the other of all MSC samples. Control was performed using Fluorescence minus one. The
following markers: CD105, CD34, CD45 and CD90 were used in every tube in order to diminish the auto-fluorescence presented by MSC, therefore
these were not contemplated in this analysis, and were validated in frozen tissue from EWS samples. (B) IHC studies in frozen tissue from EWs
samples. Upper panel represents EWS typical morphology as well as CD99 strong expression. Middle panel shows that a strong expression of CD90
and positivity for CD105. Finally, lower panel shows that EWS present negative expression of both CD45 and CD34.
doi:10.1371/journal.pone.0085814.g004
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included HD, EWS-P and a set of controls, Adipose and Placenta
derived MSC (Figure 4A). Additionally, we evaluated the
expression of the base markers CD90, CD105, CD45 and CD34
one by one in a set of EWS samples (n = 9) by IHC. The EWS
samples presented the typical small round cell morphology and
strong CD99 expression as observed on Figure 4B top panel.
CD90 (Thy-1) was strongly expressed in all EWS samples.CD105
(endoglin) was positively expressed in tumor cells and strongly
expressed in the cells surrounding the tumor vessels (Figure 4B
middle panel). Regarding hematopoietic markers CD34 and
CD45, all EWS samples showed negative expression in the tumor
cells (Figure 4B lower panel). Results were homogeneously
observed in all EWS samples analyzed. Expression of CD90,
CD105, CD34 and CD45 in EWS cell lines, in comparison with
MSC-HD and MSC-P is detailed on Figure S1.
MSC derived from EWS patients presented lower levels of
CD99 expression than that of EWS cells
CD99 transmembrane glycoprotein overexpression is routinely
used as a diagnostic marker of EWS. Herein, we observed that
MSC-P presented low to moderate levels of CD99 expression,
similarly to MSC-HD and significantly lower than EWS cell lines
(p = 0,001) (Figure 3C). As depicted in Table 1, MSC-P
presented comparable intensity levels of CD99 expression between
them. Interestingly, both patients MSC-P-05 and MSC-P-11
presented the primary tumor in the same bone from which MSC
were collected (iliac bone). Despite being closer to the primary
tumor, this MSC presented comparable levels of CD99 intensity to
the other patients. MSC-P presented CD99 levels of expression
lower than EWS cell lines, with the exception of the RDES cell
line, which presented the lowest CD99 intensity. (Figure 3B)
CD99 is heterogeneously expressed in MSC from
different tissue sources
We extended our study on CD99 expression to MSC derived
from different sources of healthy tissues (BM, iliac crest, amnios,
chorion, dental pulp, adipose tissue, and placenta). In this new set
of BM-MSC samples, we observed that CD99 expression was also
quite variable, ranging from negative to overtly positive (Table 2).
Regarding MSC from other healthy tissues, all samples with the
exception of 2 amnios and 2 adipose derived samples, presented
positive CD99 expression (Table 2). Overall, weak to highly
positive expression of CD99 was found in 17 out of 23 (71%) MSC
samples. Of these, at least 11 MSC (scored as ++ and +++)
showing expression levels similar to those found in EWS cell lines.
CD99 engagement does not elicit impairment of MSC
survival
We evaluated whether engagement of CD99 with 0662 MAb
was able to induce apoptosis as previously shown in EWS cells and
MSC (Figure 5A) [27,28]. Cell cultures from different BM-MSC
(n = 5) positive for CD99 at similar levels, were exposed to anti-
CD99 MAb and RDES was used as a control (Figure 5B). We
observed that a mere 15 minute-treatment was enough to induce a
27% of apoptotic cells in RDES (p,0.05), whereas the same
treatment regimen only triggered a 7% of apoptotic population in
MSC (Figure 5C). Furthermore, 4 hours of treatment lead to an
almost complete apoptotic RDES culture (73% annexin-V positive
cells) (p,0.05) but failed to increase significantly the initial
percentage of apoptosis in MSC (Figure 5D).
Discussion
Previous evidence suggesting that MSC would be the most
plausible cell of origin of EWS have stressed the need for deeper
studies of BM-MSC derived from EWS patients. Clinically, the
diagnosis of EWS is based on morphology, by the presence of the
EWSR1-ETS fusions, and the cell surface over expression of
CD99 [1]. The primary aim of our study was to determine early
events in MSC-P, such as the presence of EWSR1-ETS fusions
and differential phenotypic patterns, as a way to unveil cellular
predispositions that could be exploited in therapy. Specifically; we
observed that MSC-P lacked the presence of the EWSR1-FLI 1
fusion gene and further EWSR1 rearrangements. These results
were validated at the DNA and mRNA level. This might not be
surprising, but it is important given that previous studies
performed in Leukemia described that fusion of the MLL
(HRX, ALL-1) gene with its partners, initially arises in prenatal
myeloid cells, which are pre-malignant, which after stages of
progression during development result in fully malignant leuke-
mic-cells in the adult [29].
Subsequently we analyzed the presence of EWS surface
markers. Our goal was to determine events occurring prior to
the translocation that could enable a permissive environment for
cell transformation and perhaps help solve the causal dilemma of
what came first, the EWSR1 fusion or secondary alterations: the
Table 2. CD99 expression in MSC derived from healthy
tissues.
Sample CD99 MFI1 PN2 Localization
BM-DN-TD ++ P4 Iliac crest
BM-DN-HB ++ P5 Iliac crest
BM-DN-001 +++ P6 Iliac crest
BM-DN-005 +++ P6 Iliac crest
BM-DN-HU-1 + P4 Iliac crest
BM-DN-HU-2 + P4 Iliac crest
BM-DN-TD2 ++ P4 Iliac crest
DP-CM ++ P5 Dental Pulp
DP-15 ++ P6 Dental Pulp
DP-49 ++ P6 Dental Pulp
COR-3442 + P5 Chorion
COR-3386 + P5 Chorion
COR-3412 + P6 Chorion
AM-3481 2 P6 Amnios
AM-3386 +/2 P6 Amnios
AM-3396 2 P5 Amnios
PLD-2 ++ P4 Placenta
PLD-3 ++ P4 Placenta
PLD + P5 Placenta
AD-HADAS +/2 P4 Adipose Tissue
AD-HADAS-1 2 P3 Adipose Tissue
AD-ADIPO3412 2 P5 Adipose Tissue
AD-002 ++ P4 Adipose Tissue
CD99 expression levels in MSC derived from normal tissue, including BM; dental
pulp; adipose tissue; chorion; amnios and placenta. Again, intensity levels for
CD99 expression were variable with 11/19 samples presenting moderate/high
expression (scores +++ and ++); 8/19 presenting low levels of expression and 4/
19 with negative CD99 expression. Samples were studied between passages 4
and 6.
1MFI stands for Median Fluorescence Intensity,
2PN stands for Passage Number.
doi:10.1371/journal.pone.0085814.t002
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chicken or the egg? [30]. Our results, however, suggest that the
immunophenotypic profiles of MSC-P and MSC-HD, are similar
regarding EWS surface markers CD99, CD271, CD54 and
CD117. Notwithstanding, our study also revealed that both
EWS cell lines and EWS samples display MSC features such as the
expression of CD90 and CD105 and the lack of the hematopoietic
markers. The absence of CD34 expression in EWS cell lines and
samples, is in fact very interesting, given that autologous stem cell
transplantation has already been considered in clinical trials for
EWS [31]. Our results rule out the possibility of contamination of
the CD34+ niche with tumor cells in auto transplantation.
In line of the above, we cannot discard the possibility of a
cellular hierarchy between MSC expressing CD99; cellular pre-
malignant stages presenting EWSR1 gene rearrangements and
gene deregulation, gradually losing MSC phenotype and; finally a
fully malignant EWS cell bearing the EWSR1 fusion, overex-
pressing CD99 and maintaining some MSC phenotypical charac-
teristics such as CD90 and CD105.
Since MSC also express CD99, and taking into account that
CD99 is a promising target for innovative therapies in EWS, we
felt the need to study possible cytotoxic effects of anti-CD99
therapies on MSC. CD99 is, in fact, overexpressed in over 99% of
EWS cells and has been considered as a key causative of EWS
malignancy and a potential therapeutic target [1,3]. Contradictory
data suggest that on the one hand, induced expression of EWSR1-
FLI1 upregulates CD99. On the other hand, however, when
EWSR1-FLI1 was knocked down in EWS no changes in CD99
expression were reported [6,11,32].These observations may
actually be reconclied by our finding that MSC show variable
baseline expression levels of CD99. The physiological functionality
of CD99 remains unknown, but CD99 knockdown in EWS cells
induced their neural differentiation and reduced cell malignancy
[33]. Altogether, our previous data confirmed that both EWSR1-
FLI1 and CD99 are absolutely critical for EWS oncogenic
phenotype maintenance [33]. Additionally, in EWS, the engage-
ment of CD99 with antibodies resulted in apoptosis of EWS cells
[34–36]. Here, we observed that MSC displaying similar CD99
expression levels to EWS cells were unable to undergo apoptosis
when exposed to 0662. This finding is of particular interest in
terms of future clinical application of CD99 targeted therapies,
since it sustains the limited toxicity to MSC and potentially high
specificity of this therapeutic approach in EWS patients. However,
toxicity towards other cell types expressing CD99, should also be
tested.
In conclusion, i) MSC-P behave like MSC-HD and are
phenotypically different from EWS cells; ii) CD99 is variably
expressed among MSC derived from normal tissues, and finally iii)
anti-CD99 therapies induce massive cell death in EWS cells while
Figure 5. Cytofluorimetric analysis of CD99 expression on RD-ES cell line and BM-MSC. A) Dotted line represents cells stained with
secondary antibody alone; solid profile represents cells stained with anti-CD99 antibody. In each panel, the ordinate represents the number of cells.
All the 5 MSC used for functional assays presented similar levels of CD99 expression. (B) Time-course analysis of apoptosis after exposure to anti-CD99
0662 MAb. RD-ES is used as positive control. Cell death was determined by examining annexin V-FLUOS binding with flow cytometry. Early-apoptotic
cells were annexin V-positive and PI -negative (Lower-Right region). Late apoptotic/necrotic cells were annexin V- and PI-positive (Upper-Right
region). Results shown here are representative of all the 5 CD99-highly positive MSC. (C) Percentage of living, apoptotic and necrotic cells observed in
cells (two representative cultures of BM-MSC and RD-ES EWS cell line) treated with anti-CD99 MAb for 15 min or (* represents statistical significance in
comparison to control p,0,05)(D) 4 hrs. The assay was performed on detached cells. The EWS cell line shows an increment in the percentage of
apoptotic and necrotic cells after CD99 engagement, whereas the BM-MSC show similar percentages of alive and dying cells in treated or untreated
conditions. (* represents statistical significance in comparison to control p,0,05).
doi:10.1371/journal.pone.0085814.g005
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maintaining viability and integrity of MSC with similar CD99
expression.
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